l e t t e r s
To identify genetic factors contributing to amyotrophic lateral sclerosis (ALS), we conducted whole-exome analyses of 1,022 index familial ALS (FALS) cases and 7,315 controls. In a new screening strategy, we performed gene-burden analyses trained with established ALS genes and identified a significant association between loss-of-function (LOF) NEK1 variants and FALS risk. Independently, autozygosity mapping for an isolated community in the Netherlands identified a NEK1 p.Arg261His variant as a candidate risk factor. Replication analyses of sporadic ALS (SALS) cases and independent control cohorts confirmed significant disease association for both p.Arg261His (10,589 samples analyzed) and NEK1 LOF variants (3,362 samples analyzed). In total, we observed NEK1 risk variants in nearly 3% of ALS cases. NEK1 has been linked to several cellular functions, including cilia formation, DNA-damage response, microtubule stability, neuronal morphology and axonal polarity. Our results provide new and important insights into ALS etiopathogenesis and genetic etiology.
In recent years, the combination of exome sequencing, segregation analysis and bioinformatic filtering has proven to be an effective strategy to rapidly identify new disease genes 1 . Unfortunately, this method can be difficult to apply to disorders such as ALS, for which late age of onset and low-to-modest variant penetrance make it difficult to obtain large informative multigenerational pedigrees. Owing to high genetic heterogeneity, ALS is also difficult to analyze using filtering methods designed to exploit unrelated patient groups 2 . Recently, we had demonstrated the utility of exome-wide rare variant burden (RVB) analysis as an alternate approach, identifying a replicable association between FALS risk and TUBA4A in a cohort of 363 cases 3 . In brief, RVB analysis is used to compare the combined frequency of rare variants in each gene in a case-control cohort. Candidate associations are identified by significant differences after multipletest correction. Since this initial study, we extended our data set to include complete exome sequencing for 1,376 index FALS cases and 13,883 controls. Of these, 1,022 cases and 7,315 controls met all required data, inter-relatedness and ancestral quality control criteria ( Supplementary Figs. 1 and 2 , and Online Methods).
Successful detection of disease associations through RVB analysis can depend heavily on the appropriate setting of test parameters. As genetic loci often contain many alleles of no or low effect, prior filtering of variants based on minor allele frequency (MAF) and pathogenicity predictors can identify disease signatures otherwise masked by normal human variability. As appropriate MAF or pathogenicity predictor settings may not be obvious in advance, comprehensive assessment of all pursuable analysis strategies is desirable but can in turn introduce excessive multiple-test burden. To overcome these limitations, we performed 308 distinct RVB analyses of ten well-established ALS genes using 44 functional and 7 MAF filters (Fig. 1a) . All tests included correction for gene coverage and ancestral covariates (Online Methods). In the final cohort, 72 cases and 0 controls harbored known ALS pathogenic mutations in these ten genes (Online Methods). An additional 26 cases harbored a repeat expansion in the C9orf72 gene. Tests differed in their capacity to detect individual known ALS genes (Supplementary Table 1 ), but we achieved the highest net sensitivity when we restricted analyses to variants with MAF < 0.001 and functional classifications of either nonsense, splice-altering 4 or deemed deleterious by functional analysis through hidden Markov models (FATHMM) 5 . Under these settings, four genes exhibited disease association at exome-wide (Bonferronicorrected P < 2.5 × 10 −6 ) significance (SOD1, TARDBP, UBQLN2 and FUS), three achieved near exome-wide significance (TUBA4A, TBK1 and VCP), and three displayed modest to marginal disease association (PFN1, VAPB and OPTN) (Fig. 1b) . Genes exhibiting the strongest disease associations included those reported as major ALS genes in population-based studies, whereas those exhibiting weaker associations are believed to constitute rarer causes of disease.
Extension of the optimal known ALS gene parameters to all proteincoding genes identified one new gene displaying exome-wide significant disease association (Fig. 1b) . The gene, NEK1 (odds ratio (OR) = 8.2, P = 1.7 × 10 −6 ), encodes the serine/threonine kinase NIMA (never in mitosis gene-A)-related kinase. Retesting NEK1 under alternate analysis parameters identified strong disease associations across most analysis strategies, particularly where we included LOF (nonsense and predicted splice-altering) variants (Supplementary Table 2 and Supplementary Fig. 3 ). We observed no evidence for systematic genomic inflation (λ = 0.95), confounding related to sample ascertainment ( Supplementary Fig. 4 ) or case-control biases in NEK1 gene coverage (Supplementary Fig. 5 ). Removal of samples carrying rare variants of known ALS genes did not influence the association (OR = 8.9, P = 7.3 × 10 −7 ).
In an independent line of research, we performed whole-genome sequencing for four ALS patients from an isolated community in the Netherlands (population < 25,000). We observed high inbreeding coefficients for each of the four patients, confirming their high degree of relatedness and supporting a restricted 1 0 3 8 VOLUME 48 | NUMBER 9 | SEPTEMBER 2016 Nature GeNetics l e t t e r s genetic lineage (Supplementary Fig. 6 ). Autozygosity mapping, allowing for genetic heterogeneity, identified four candidate disease variants occurring in detectable runs of homozygosity (ROH) (Supplementary Fig. 7 ). These variants included a p.Arg261His variant of NEK1. Two of the four SALS cases were homozygous for p.Arg261His and two were heterozygous, raising the possibility that even a single copy of the allele may increase disease risk. Clinical evaluation of the four cases did not find any overt differences in disease phenotype. None of the other three candidate variants exhibited homozygosity in multiple patients or occurred at all in more than two patients. Analysis of the region identified a shared p.Arg261His haplotype spanning 3 Mb in all four samples (Supplementary Table 3) .
To validate the risk effects of p.Arg261His, we tested for disease association among 6,172 SALS cases and 4,417 matched controls from eight countries ( Supplementary Figs. 8 and 9 , and Online Methods). We genotyped this cohort using the Illumina exome chip or by whole-genome sequencing, allowing for checking of any overlap or detectable relatedness to the FALS case-control cohort, which was not present. Meta-analysis of all independent population strata identified a clear minor allele excess in cases with a combined significance of P = 4.8 × 10 −5 and OR = 2.4 ( Fig. 2) . We also observed disease association in the FALS case-control data (OR = 2.7, P = 1.5 × 10 −3 ) and a meta-analysis of FALS, SALS and all controls combined (OR = 2.4, P = 1.2 × 10 −7 ).
DNA availability facilitated segregation analysis of only one NEK1 LOF variant, a p.Arg550* variant, which we also detected in the affected mother of the identified proband. To validate the effect of LOF variants observed in FALS and assess any potential contribution to sporadic disease, we analyzed full sequencing data of the NEK1 coding region for 2,303 SALS cases and 1,059 controls (Supplementary Table 2) . Meta-analysis of discovery and replication LOF analyses yielded a combined significance of P = 3.4 × 10 −8 and OR = 8.8.
In total, we detected 120 predicted nonsynonymous NEK1 variants in FALS samples, SALS samples and controls. These were distributed throughout the gene including in the sequence encoding protein kinase domain (PKD) and six coiled-coil domains thought to be involved in mediating protein-protein interactions ( Supplementary  Fig. 3 ). After conditioning for LOF variants and p.Arg261His, we observed tentative excesses of case variants in analyses of rarer variant categories, but larger sample sizes will be required to confirm the pathogenicity beyond p.Arg261His and LOF variants (Supplementary Table 4 ). Analysis of other members of the NEK gene family (NEK2−NEK11) identified no associations in the FALS data set meeting multiple-test criteria (Supplementary Table 5) .
Although no other gene achieved discovery significance, ten candidate loci exhibited P < 1.0 × 10 −3 in the FALS discovery analysis ( Table 1) . These included the gene encoding the SNARE (soluble NSF attachment protein receptor) complex protein synataxin 12 (STX12, OR = 33.1, P = 9.7 × 10 −5 ). Analysis of the SALS replication cohort identified missense variants in 5/2,303 cases versus 0/1,059 in controls. However, the cohort was not sufficiently powered to assess events of this frequency, and larger sample sizes will be required to establish effects on ALS risk (Supplementary Table 6 ). Another identified candidate gene was the known hereditary spastic paraplegia gene KIF5A 6 (OR = 7.1, P = 4.8 × 10 −4 ); however, no observed elevations in patient variant frequencies within the SALS replication cohort reached statistical significance (Supplementary Table 7) . npg l e t t e r s NEK1 has been previously described as a candidate gene for ALS 7, 8 . Here our findings show that NEK1 in fact constitutes a major ALS-associated gene with risk variants present in ~3% of European and European-American ALS cases. We identified LOF variants in 1.2% of FALS samples (OR = 8.2) and 1.0% of SALS samples (OR = 22.2) versus 0.17% of controls, whereas we identified the p.Arg261His variant in 1.7% of FALS samples (OR = 2.7) and 1.6% of SALS samples (OR = 2.4) versus 0.69% of controls. We identified variants of unknown clinical importance (missense, MAF < 0.001) in a further 1.8% of FALS samples and 1.3% of SALS samples versus 1.2% of controls. In comparison, risk variants in previously established ALS genes occur at approximately the following percentages: C9orf72, <10%; SOD1, <2%; TARDBP, <1%; FUS, <1%; and others, <<1% or uncertain [9] [10] [11] [12] . However, caution must be taken when comparing the frequency of variants or mutations that differ in penetrance (i.e., highly penetrant mutations to lower-penetrance risk variants). Furthermore, assessment of the true odds ratio for variants in a gene may be difficult because of the presence of neutral variants that dilute out the observed effect. The actual odds ratio may therefore be even higher for specific subsets of patient variants. The LOF variants in NEK1 displayed a higher odds ratio relative to p.Arg261His. The p.Arg261His variant occurs adjacent to the protein kinase domain and is classified as deleterious by most bioinformatic prediction algorithms (SIFT, PolyPhen, LRT, MutationTaster, Mutation Assessor, PROVEAN, CADD, GERP and SiPhy). One model to account for the difference in p.Arg261His and LOF variant toxicity could be a correlation between phenotypic expression and the predicted extent of NEK1 LOF. This model would also be consistent with previous findings that homozygosity for NEK1 LOF variants causes a severe developmental phenotype; short rib polydactyly syndrome type II (SRPS) 13 . In the current study, no individuals carried multiple LOF alleles. However, in SRPS, homozygous carriers of NEK1 LOF variants have been reported to exhibit a 64% reduction of NEK1 mRNA levels whereas unaffected heterozygous parents exhibit a 30-40% reduction 13 .
NEK1 represents one of 11 members of the highly conserved NIMA kinase family, which has conserved functions in cell-cycle progression and mitosis. In postmitotic cells, NEK1 is a primary regulator of the formation of nonmotile primary cilium 14, 15 . Disruption in the structure or function of primary cilia has been linked to neurological defects such as brain dysgenesis, hydrocephalus and intellectual disability 16, 17 , and abnormalities in cilia number, structure and microtubule state occur in fibroblasts derived from SRPS patients homozygous for NEK1 truncation variants 13 . In vitro disruption of the activity of other neuronally expressed NEK family members has similarly been shown to disrupt neuronal morphology, neurite outgrowth, microtubule stability and microtubule dynamics 18, 19 . Microtubule integrity and kinesin and dynein intraflagellar transport are essential to maintain cilia structure and function. This is of particular relevance as disruption of the microtubule cytoskeleton has been associated to the development of ALS 3 , and mutations of the dynein subunit dynactin are associated with motor neuron degeneration 20 . Additionally, motor neurons derived from mice expressing human SOD1 G93A show a selective loss of cilia both in vitro and in vivo 21 . Besides its role in ciliogenesis, NEK1 is also known to regulate mitochondrial membrane permeability 22 and DNA repair 23 . Both of these processes have been extensively investigated in relation to ALS, and have been postulated to explain the toxicity of ALSassociated mutations in SOD1 and FUS 24, 25 . Mutations in DNA-repair genes cause several early-onset neurological phenotypes, and multiple lines of evidence suggest defective DNA repair may contribute to both late-onset neurodegeneration and brain aging in general 26 . For example, oxidative damage and DNA strand breaks have been observed to be elevated in ALS, Alzheimer's disease and Parkinson's disease cases 27 , and a recent large-scale genome-wide association study (GWAS) implicated DNA-repair genes as age-of-onset modifiers in Huntington's disease 28 . The pathological importance of DNA damage in ALS, and whether modifier effects observed in Huntington's disease may generalize to repeat-expansion disorders such as C9orf72-associated ALS, constitute important questions to be addressed. 
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Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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